



The Omics Techniques in Obstetrical Pathologies

Guest Editor:

Dr. Silvia Visentin

Gynecology and Obstetrics Unit,
Department of Women's and
Children's Health, University of
Padua, Padua, Italy

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editor

Dear Colleagues,

Modern omics or Multi-Omics techniques, such as Genome, transcriptome, proteome and metabolome, are currently of great attention in the scientific, medical, and obstetrics/gynecological fields.

The Omics Techniques study of the etiopathogenetic processes that underlie the development of obstetric or gynecological pathologies, such as pre-eclampsia, growth retardation, the threat of preterm birth, endometriosis, oncological pathology can lead to the identification of new therapeutic strategies. At the same time, the study of cellular, gene and transmission functions are also important. The aim of the special issue is to collect the latest research results of Omics Techniques application in obstetric diseases.

- genome
- transcriptome
- proteome
- metabolome
- Multi-Omics
- obstetric pathologies
- gynecological pathologies
- therapy





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)